Biosimilars: The Next Wave of Health Care Cost Savings

  • November 28, 2017
  • 2:00 PM – 3:00 PM ET
  • Online
about

Biosimilars are a new drug category and major opportunity for savings in health care with estimates ranging from $44B and upwards. Biosimilars should also increase patient access through lower costs due to competition. Being a new category means that education on what biosimilars are is critically needed among all stakeholders.

Additionally all stakeholders must operationally prepare to take advantage of the new opportunity that biosimilars represent. That is not current state of affairs.

The webinar will provide some core information about the definition of biosimilars per the FDA. Furthermore the webinar will outline some specific issues that need to be addressed in order for the biosimilar opportunity to be capitalized on.

Webinar participants will learn:

  • The definition of a biosimilar, including “sameness”
  • The FDA approach to approving biosimilars (analytical vs. clinical)
  • Operational issues inhibiting the uptake of biosimilars and possible solutions

Who should attend: Health plan leaders and decision makers


Speakers:


Carlos Sattler,Vice President, Clinical Development & Medical Affairs
Dr. Carlos Sattler is the Head of Clinical Development and Medical Affairs at Sandoz Inc. In that capacity, Dr. Sattler leads efforts in the US to develop and implement Sandoz’ medical and scientific strategy, medical education and communication initiatives, and data generation activites in support of biosimilars and other Sandoz products.  Dr. Sattler also participates in the development of the strategic plan for acquisition and clinical development of new products in the Sandoz pipeline. Dr. Sattler joined Sandoz from Merck & Co., Inc. where he served in various clinical research and medical affairs roles, with a primary focus on the development and commercialization of Merck’s human papillomavirus vaccine.  Dr. Sattler specialized in pediatric medicine and is subspecialty trained in pediatric infectious diseases.

 

Mark Vineis, Vice President, Managed Care & Specialty Services
Mark has over twenty years of industry experience and is the Vice President of Managed Markets and Specialty Services at Sandoz Biopharma, a division of Novartis. His team is fully dedicated to commercializing the organization’s biosimilar portfolio.  Prior to joining Sandoz, Mark was the General Manager of Specialty Pharmacy for Cardinal Health.  Mark also spent seven years at Genentech, where he led several teams including pricing, contracting strategy, channel strategy and managed care marketing.   Previously, he held pricing, account management, marketing and sales roles at GlaxoSmithKline and AstraZeneca.